Know Cancer

or
forgot password

Pathologic Effects of Neoadjuvant Radiation Therapy in Operable Early Stage Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Early Stage Non-small Cell Lung Cancer

Thank you

Trial Information

Pathologic Effects of Neoadjuvant Radiation Therapy in Operable Early Stage Lung Cancer


Inclusion Criteria:



- Proof of cT1a/b - 2a/b N0M0 NSCLC

- Informed Consent signed

- Resectable tumour

- Operable patient

- > 18 years old

- men and women

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

pathological effects of hypofractionated radiation therapy

Outcome Description:

To describe the pathological effects of hypofractionated radioation therapy (RT) and to address the relationship with blood and tissue biomarkers and bio-imaging.

Outcome Time Frame:

at 2 years

Safety Issue:

No

Principal Investigator

Jan Van Meerbeeck, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospital Ghent, Belgium

Authority:

Belgium: Ethics Committee

Study ID:

2010/204

NCT ID:

NCT01138722

Start Date:

May 2010

Completion Date:

May 2017

Related Keywords:

  • Early Stage Non-small Cell Lung Cancer
  • early stage non-small cell lung cancer
  • hypofractionated radiation therapy
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location